Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
January 02, 2024 07:05 ET
|
Virios Therapeutics
ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on developing novel antiviral therapies to...
BCLI FINAL DEADLINE TOMORROW: ROSEN, A TOP RANKED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Filed by the Firm – BCLI
January 01, 2024 13:55 ET
|
The Rosen Law Firm PA
NEW YORK, Jan. 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between...
BCLI DEADLINE ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action Commenced by the Firm – BCLI
December 28, 2023 17:03 ET
|
The Rosen Law Firm PA
NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between...
MIST NEWS: ROSEN, A LEADING LAW FIRM, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – MIST
December 28, 2023 16:01 ET
|
The Rosen Law Firm PA
NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Milestone...
Milestone Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
December 26, 2023 10:55 ET
|
Block & Leviton LLP
BOSTON, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Milestone Pharmaceuticals, Inc. (NASDAQ: MIST) for potential securities law violations. Investors who have lost money...
BioNTech und DualityBio erhalten Breakthrough-Therapy-Status der FDA für ADC-Kandidaten BNT323/DB-1303 zur Behandlung von Gebärmutterkrebs
December 21, 2023 08:00 ET
|
BioNTech SE
Breakthrough-Therapy-Status basiert auf Phase-1/2-Daten zur Sicherheit und Wirksamkeit in Patientinnen mit Human Epidermal Growth Factor Receptor 2 („HER2“) -exprimierendem, fortgeschrittenen...
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
December 21, 2023 08:00 ET
|
BioNTech SE
Designation is based on Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced endometrial cancer with encouraging early signs of...
Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine
December 19, 2023 09:00 ET
|
Processa Pharmaceuticals, Inc.
FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU Interim analysis of the NGC-Cap Phase 1b data shows improved...
MAPS Celebrates Submission of New Drug Application to FDA for MDMA-Assisted Therapy for PTSD
December 13, 2023 18:16 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
The first NDA submission for any psychedelic-assisted therapy has been submitted through a 30-year effort initiated and led by the nonprofit MAPS
Accountability Needed for COVID Debacle, according to the Journal of American Physicians and Surgeons
December 13, 2023 11:51 ET
|
Association of American Physicians and Surgeons
Regulatory agencies and individuals, that have pervasive conflicts of interest, need to be held accountable for the disastrous COVID-19 response.